Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 13/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205482 | 0.88 | CACNA1H (0.55) | CACNA1HTRPV1SMN1; SMN2 | |
| SCHEMBL14263432 | 0.88 | CACNA1H (0.54) | CACNA1HTRPV1MEN1KMT2A | |
| SCHEMBL8217839 | 0.86 | CACNA1H (0.49) | CACNA1HTRPV1MEN1KMT2A | |
| SCHEMBL8209853 | 0.86 | TRPV1 (0.55) | CACNA1HTRPV1HTTSMN1; SMN2NPSR1 | |
| SCHEMBL8210646 | 0.86 | GPR119 (0.52) | CACNA1H | |
| SCHEMBL8202849 | 0.86 | CACNA1H (0.49) | CACNA1HTRPV1MEN1KMT2AHTT | |
| SCHEMBL12876068 | 0.85 | ALDH1A1 (0.54) | CACNA1HTRPV1MEN1KMT2A | |
| SCHEMBL8218916 | 0.84 | CACNA1H (0.57) | CACNA1HTRPV1 | |
| SCHEMBL8212128 | 0.84 | STS (0.46) | CACNA1HTRPV1 | |
| SCHEMBL8224619 | 0.83 | CACNA1H (0.46) | CACNA1HMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008033464-A2 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |